Dehydrocholic acid
description1
description2
Basic information
Product Name: Dehydrocholic acid
CAS No.: 81-23-2
Molecular Formula: C₂₄H₃₄O₅
IUPAC Name: 3α-Hydroxy-7,12-dioxo-5β-cholan-24-oic acid
Appearance & Solubility:
Property |
Specification |
Appearance |
White crystalline powder |
Water Solubility |
0.5 mg/mL (free acid) |
0.1M NaOH Solubility |
300 mg/mL |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Dehydrocholic acid(CAS: 81-23-2) |
98.5% by titration |
Loss on drying |
≤1.0% |
Residue on ignition |
≤0.3% |
Structural Modification
C7/C12 keto groups (enhanced water solubility, logP=1.2)
Functional Advantages
Stimulates bile secretion (↑50-70% bile flow)
No enterohepatic recirculation (reduced hepatotoxicity risk)
Pharmacopoeial Standards
USP-NF, EP 11.0, and ChP 2020 require ≥98.5% purity
Applications
Therapeutic Uses
Choleretic Action:
Promotes hepatocyte secretion of low-viscosity bile (↓30% viscosity)
Used for post-surgical biliary drainage obstruction
Diagnostic Aid:
Gallbladder contraction assessment (ultrasound contrast enhancer)
Industrial Applications
Field |
Application |
Example Products |
Pharmaceutical Excipients |
Solubilizer for poorly soluble drugs |
Albendazole nanosuspensions |
Cosmetics |
Transdermal penetration enhancer |
Anti-aging serums |
1. Choleretic Mechanism
2. Molecular Targets
Target |
Effect |
EC50 |
AE2 Transporter |
Stimulates HCO₃⁻ secretion |
50 μM |
CFTR Chloride Channel |
Enhances Cl⁻ efflux |
100 μM |
Formulations
Form |
Specification |
Features |
Tablets |
250mg/tablet |
Enteric-coated (acid-resistant) |
Injection |
50mg/5mL |
Requires glucose dilution |
Dosing Regimens
Indication |
Dose |
Duration |
Postoperative Cholestasis |
250mg tid |
7-10 days |
Chronic Cholecystitis |
250mg bid |
4-8 weeks |
Safety Profile
Adverse Reactions
System |
Effect (Incidence) |
Management |
Gastrointestinal |
Diarrhea (15%) |
Dose reduction/split dosing |
Hepatobiliary |
Transient ALT elevation (5%) |
Discontinuation (reversible) |
Drug Interactions
Enhanced Effects: Reduce dose by 30% when combined with choleretic herbs (e.g., Artemisia capillaris)
Contraindicated Combinations: Cholestyramine (>90% adsorption)
Research Progress Green max
Novel Formulations
Sustained-Release Pellets:Ethyl cellulose coating (12-hour release)
Nanoemulsions:Soybean phospholipid carrier (↑80% bioavailability)
New Indications
Non-Alcoholic Fatty Liver:Activates FXR receptors (↓40% steatosis in animal models)
Gut Barrier Protection:Reduces LPS-induced intestinal damage (↑2× ZO-1 expression)
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.